31.48
-0.92 (-2.84%)
| Previous Close | 32.40 |
| Open | 32.36 |
| Volume | 216,737 |
| Avg. Volume (3M) | 392,355 |
| Market Cap | 591,088,192 |
| Price / Book | 2.35 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Diluted EPS (TTM) | -3.14 |
| Total Debt/Equity (MRQ) | 0.87% |
| Current Ratio (MRQ) | 22.92 |
| Operating Cash Flow (TTM) | -62.89 M |
| Levered Free Cash Flow (TTM) | -69.56 M |
| Return on Assets (TTM) | -22.89% |
| Return on Equity (TTM) | -41.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Tectonic Therapeutic, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | 1.5 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.90 |
|
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 38.29% |
| % Held by Institutions | 59.27% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Aberdeen Group Plc | 31 Dec 2025 | 1,141,824 |
| 5Am Venture Management, Llc | 31 Dec 2025 | 606,660 |
| Vestal Point Capital, Lp | 31 Dec 2025 | 328,000 |
| Bollard Group Llc | 31 Dec 2025 | 302,953 |
| Pale Fire Capital Se | 31 Dec 2025 | 261,026 |
| 52 Weeks Range | ||
| Median | 60.00 (90.60%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 08 Jan 2026 | 60.00 (90.60%) | Buy | 21.46 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MCNAMARA PETER | - | 35.87 | -6,262 | -224,618 |
| RUDDY MARCELLA K. | - | 35.87 | -10,000 | -358,700 |
| Aggregate Net Quantity | -16,262 | |||
| Aggregate Net Value ($) | -583,318 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 35.87 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MCNAMARA PETER | Officer | 06 Mar 2026 | Automatic sell (-) | 6,262 | 35.87 | 224,618 |
| MCNAMARA PETER | Officer | 06 Mar 2026 | Option execute | 2,715 | - | - |
| RUDDY MARCELLA K. | Officer | 06 Mar 2026 | Automatic sell (-) | 10,000 | 35.87 | 358,700 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |